Pharmacokinetics of Dactinomycin in a Pediatric Patient Population: a United Kingdom Children’S Cancer Study Group Study Gareth J

Total Page:16

File Type:pdf, Size:1020Kb

Pharmacokinetics of Dactinomycin in a Pediatric Patient Population: a United Kingdom Children’S Cancer Study Group Study Gareth J Cancer Therapy: Clinical Pharmacokinetics of Dactinomycin in a Pediatric Patient Population: a United Kingdom Children’s Cancer Study Group Study Gareth J. Veal,1 Michael Cole,1 Julie Errington,1 Annie Parry,2 Juliet Hale,2 Andrew D.J. Pearson,2 Karen Howe,3 Julia C. Chisholm,3 Carol Beane,4 Bernadette Brennan,4 Fiona Waters,5 Adam Glaser,5 Sue Hemsworth,6 Heather McDowell,6 Yvonne Wright,7 Kathy Pritchard-Jones,7 Ross Pinkerton,7 Gail Jenner,8 James Nicholson,8 Ann M. Elsworth,9 Alan V. Boddy,1 and UKCCSG Pharmacology Working Group Abstract Purpose: Dactinomycin (actinomycin D) is an antitumor antibiotic used routinely to treat certain pediatric and adult cancers. Despite concerns over the incidence of toxicity, little is known about the pharmacology of dactinomycin. A study was done to investigate dactinomycin pharmaco- kinetics in children. Experimental Design: Dactinomycin was administered to 31patients by bolus i.v. infusion, at doses of 0.70 to1.50 mg/m2. Plasma concentrations were determined by liquid chromatography- mass spectrometry up to 24 hours after drug administration and National Cancer Institute Com- monToxicity Criteria was assessed. Results: Pharmacokinetic data analysis suggested that a three-compartment model most accurately reflected dactinomycin pharmacokinetics. However, there was insufficient data avail- able to fully characterize this model. A median peak plasma concentration (Cmax)of25.1ng/mL (range, 3.2-99.2 ng/mL) was observed at 15 minutes after administration. The median exposure (AUC0-6), determined in 16 patients with sampling to 6 hours, was 2.67 mg/L.min (range, 1.12-4.90 mg/L.min). After adjusting for body size, AUC0-6 and Cmax were positively related to dose (P =0.03andP = 0.04, respectively). Patients who experienced any level of Common Toxicity Criteria grade had a 1.46-fold higher AUC0-6, 95% confidence interval (1.02-2.09). AUC0-6 was higher in patients <40 kg, possibly indicating a greater toxicity risk. Conclusions: Data presented suggest that dosing of dactinomycin based on surface area is not optimal, either in younger patients in whom the risk of toxicity is greater, or in older patients where doses are capped. Dactinomycin(actinomycinD;Fig.1)isanantitumor both adults and children. The drug has been a key component antibiotic used routinely to treat certain forms of cancer in in the successful treatment of Wilms tumor patients over the past 30 years, with >80% of patients treated now being cured of the disease (1–3). However, despite its long history of clinical Authors’ Affiliations: 1Northern Institute for Cancer Research; 2School of Clinical use, limited knowledge exists concerning the relationship Medical Sciences (Child Health), University of Newcastle upon Tyne, Newcastle between dactinomycin dosing and pharmacokinetics. uponTyne; 3Department of Haematology/Oncology, Great Ormond Street Hospital, London; 4Department of Paediatric Oncology, Manchester Children’s Hospital, Dactinomycin is most commonly administered to pediatric Manchester; 5Paediatric Oncology Unit, St. James’s Hospital, Leeds; 6Royal patients as a single bolus i.v. injection. The dose is based on a Liverpool Children’s Hospital, Alder Hey, Liverpool; 7Royal Marsden Hospital, child’s calculated body surface area, with a 3- to 9-week interval 8 Surrey; Department of Paediatrics, Addenbrooke’s Hospital, Cambridge; and between courses depending on the tumor type and disease stage. 9UKCCSG, University of Leicester, Leicester, United Kingdom Received 12/13/04; revised 5/16/05; accepted 5/27/05. The dosing regimen for infants is modified, with patients <1 year Grant support: Supported in part by Cancer Research U.K. G.J. Veal was a old at diagnosis, or weighing <10 kg, frequently receiving a recipient of an AACR-GlaxoSmithKline Outstanding Clinical Scholar award. reduced dose based on body weight (4). For example, a standard The costs of publication of this article were defrayed in part by the payment of page dactinomycin dose of 1.5 mg/m2 is commonly adjusted to charges. This article must therefore be hereby marked advertisement in accordance 25 Ag/kg from birth to 6 months of age and to 1.0 mg/m2 from with 18 U.S.C. Section 1734 solely to indicate this fact. Note: This work was presented in part at the 95th Annual AACR meeting, March 27 6 months to 1 year or <10 kg body weight. This is further to 31, Orlando, FL. complicated in some clinical protocols by the fact that once a Requests for reprints: Alan V. Boddy, Northern Institute for Cancer Research, child reaches 10 kg, doses are recalculated as dose/m2 but kept at Paul O’Gorman Building, Medical School, Framlington Place, University of 50% (0.75 mg/m2) until their first birthday. Alternatively, a Newcastle uponTyne, Newcastle uponTyne NE2 4HH, United Kingdom. Phone: A 44-191-246-4412;Fax: 44-191-246-4301;E-mail: [email protected]. dose of 50 g/kg may be prescribed for children aged 1 to 3 2 F 2005 American Association for Cancer Research. years, with the conventional dose of 1.5 mg/m only being doi: 10.1158/1078-0432.CCR-04-2546 used for children >3 years of age (5). www.aacrjournals.org 5893 Clin Cancer Res 2005;11(16) August 15, 2005 Downloaded from clincancerres.aacrjournals.org on September 24, 2021. © 2005 American Association for Cancer Research. Cancer Therapy: Clinical Patients and Methods Patient eligibility and treatment. The study protocol was approved by the U.K. Trent Multicentre Ethics Committee and participating centers obtained local ethical approval; written informed consent was required, either from patients or parents as appropriate, for all patients entered onto the study. Patients 21 years or younger, receiving dactinomycin chemotherapy as part of their standard clinical treatment, were eligible (Table 1). All patients were required to have central venous access, in the form of single or double lumen central venous catheters or Port-a-Caths, in order to participate in this pharmacokinetic study. Dactinomycin (0.70-1.50 mg/m2) was administered by bolus i.v. infusion as part of the standard chemotherapy regimen that each patient was currently receiving. Toxicity was assessed by the National Cancer Institute Common Toxicity Criteria (CTC), version 2.0, Fig. 1. Chemical structure of dactinomycin (MW1,255). following dactinomycin treatment. Blood sampling and analysis. Blood samples for measurement of Dosage regimens for the treatment of patients with Wilms dactinomycin concentration were obtained from a central line prior to tumor in the U.K. have been revised on more than one occasion administration and at 15 and 30 minutes, and 1, 2, 4, 6, and 24 hours due to concerns regarding potential underdosing or a possible post-administration. Actual sampling times were recorded for all patients studied and were as follows (median value and range given): link between toxicity from venoocclusive disease of the liver 15 minutes, 17 (15-25); 30 minutes, 32 (26-50); 60 minutes, 60 and dactinomycin dosing. Similar amendments to dosing were (57-68); 120 minutes, 122 (112-132); 240 minutes, 241 (215-297); required during a Children’s Oncology Group study for the 360 minutes, 360 (330-385); 1,440 minutes, 1,440 (1,295-1,531). All treatment of rhabdomyosarcoma (5). Venoocclusive disease, a eight samples were obtained in a total of seven children, with between severe hepatic toxicity with a reported incidence of 2% to two and seven samples obtained from the remaining patients; most 13.5% across different clinical studies (6–8), is the main frequently with the omission of the 24 hours post-administration drawback to the clinical use of dactinomycin. However, despite sample. The actual number of samples obtained at each of the specified the many changes to the dosing of dactinomycin, optimum time points are given in Table 2. Samples were obtained from 17 patients dosage regimens for the treatment of infants and young with double lumen central venous catheters, 9 patients with single children remain unclear. As dactinomycin is metabolized in lumen lines, and 5 patients with Port-a-Cath access. All lines were the liver, with both the liver and kidneys involved in drug flushed thoroughly following administration of dactinomycin and prior to the withdrawal of samples for pharmacokinetic analysis and separate excretion, development of renal and hepatic function in young drug infusion and sampling sites were used whenever possible. Blood children may be an important factor in influencing its clinical samples (2 mL) were collected in heparinized tubes and centrifuged at pharmacology. This could potentially lead to significant 1,200 Â g for 10 minutes at 4jC. Plasma was separated and frozen at variations in drug pharmacokinetics between infants and older À20jC prior to analysis using a validated liquid chromatography-mass children. spectrometry assay, with a limit of quantitation of 1.0 ng/mL (13). As the dose intensity of dactinomycin treatment has been clearly defined as a significant risk factor for the development of hepatotoxicity in Wilms tumor, it would seem logical to carry out pharmacokinetic studies in these patients. This would allow Ta b l e 1. Patient characteristics potential correlations to be investigated between the extent of interpatient variation in exposure to dactinomycin and clinical Characteristic No. of patients (%) response and toxicity. However, to date, there is a paucity of Age (y) information regarding the clinical pharmacology of dactino- <511(36) mycin, with no pharmacokinetic studies having been carried 5-9 8 (26) out in pediatric patients, and a very limited number of studies 10-14 6 (19) in adults. Indeed, the only publications in this area are those 15 -20 6 (19) focusing on the analytical methods developed, with data from Sex one or two patients to show a clinical application (9–12). No Male 18 (58) dactinomycin pharmacokinetic study has been published using Female 13(42) these methods, possibly due to concerns over a lack of Diagnosis specificity for the parent drug, or due to the labor-intensive Wilms tumor 9 (29) nature of the methods, making the analysis of large numbers of Ewing sarcoma 7 (23) clinical samples unrealistic.
Recommended publications
  • Anticancer Drug Discovery from Microbial Sources: the Unique Mangrove Streptomycetes
    molecules Review Anticancer Drug Discovery from Microbial Sources: The Unique Mangrove Streptomycetes Jodi Woan-Fei Law 1, Lydia Ngiik-Shiew Law 2, Vengadesh Letchumanan 1 , Loh Teng-Hern Tan 1, Sunny Hei Wong 3, Kok-Gan Chan 4,5,* , Nurul-Syakima Ab Mutalib 6,* and Learn-Han Lee 1,* 1 Novel Bacteria and Drug Discovery (NBDD) Research Group, Microbiome and Bioresource Research Strength, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway 47500, Selangor Darul Ehsan, Malaysia; [email protected] (J.W.-F.L.); [email protected] (V.L.); [email protected] (L.T.-H.T.) 2 Monash Credentialed Pharmacy Clinical Educator, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville 3052, VIC, Australia; [email protected] 3 Li Ka Shing Institute of Health Sciences, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong, China; [email protected] 4 Division of Genetics and Molecular Biology, Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur 50603, Malaysia 5 International Genome Centre, Jiangsu University, Zhenjiang 212013, China 6 UKM Medical Molecular Biology Institute (UMBI), UKM Medical Centre, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia * Correspondence: [email protected] (K.-G.C.); [email protected] (N.-S.A.M.); [email protected] (L.-H.L.) Academic Editor: Owen M. McDougal Received: 8 October 2020; Accepted: 13 November 2020; Published: 17 November 2020 Abstract: Worldwide cancer incidence and mortality have always been a concern to the community. The cancer mortality rate has generally declined over the years; however, there is still an increased mortality rate in poorer countries that receives considerable attention from healthcare professionals.
    [Show full text]
  • Cytostatics As Hazardous Chemicals in Healthcare
    REVIEW PAPER International Journal of Occupational Medicine and Environmental Health 2019;32(2):141 – 159 https://doi.org/10.13075/ijomeh.1896.01248 CYTOSTATICS AS HAZARDOUS CHEMICALS IN HEALTHCARE WORKERS’ ENVIRONMENT ANNA PAŁASZEWSKA-TKACZ, SŁAWOMIR CZERCZAK, KATARZYNA KONIECZKO, and MAŁGORZATA KUPCZEWSKA-DOBECKA Nofer Institute of Occupational Medicine, Łódź, Poland Department of Chemical Safety Abstract Cytostatics not only induce significant side-effects in patients treated oncologically but also pose a threat to the health of occupationally exposed healthcare workers: pharmacists, physicians, nurses and other personnel. Since the 1970s numerous reports from various countries have documented the contamination of working areas with cytostatics and the presence of drugs/metabolites in the urine or blood of healthcare employees, which di- rectly indicates the occurrence of occupational exposure to these drugs. In Poland the significant scale of occupational exposure to cytostatics is also confirmed by the data collected in the central register of occupational carcinogens/mutagens kept by the Nofer Institute of Occupational Medicine. The assessment of occupational exposure to cytostatics and health risks constitutes employers’ obligation. Unfortunately, the assessment of occu- pational risk resulting from exposure to cytostatics raises a number of concerns. Provisions governing the problem of workers’ health protection are not unequivocal because they derive from a variety of law areas, especially in a matter of hazard classification and safety data sheets for cytostatics. Moreover, no legally binding occupational exposure limits have been set for cytostatics or their active compounds, and analytical methods for these substances airborne and biological concentrations are lacking. Consequently, the correct assessment of occupational exposure to cytostatics, the eval- uation of health hazards and the development of the proper preventive strategy appear difficult.
    [Show full text]
  • BC Cancer Benefit Drug List September 2021
    Page 1 of 65 BC Cancer Benefit Drug List September 2021 DEFINITIONS Class I Reimbursed for active cancer or approved treatment or approved indication only. Reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to Restricted Funding (R) provide the appropriate clinical information for each patient. NOTES 1. BC Cancer will reimburse, to the Communities Oncology Network hospital pharmacy, the actual acquisition cost of a Benefit Drug, up to the maximum price as determined by BC Cancer, based on the current brand and contract price. Please contact the OSCAR Hotline at 1-888-355-0355 if more information is required. 2. Not Otherwise Specified (NOS) code only applicable to Class I drugs where indicated. 3. Intrahepatic use of chemotherapy drugs is not reimbursable unless specified. 4. For queries regarding other indications not specified, please contact the BC Cancer Compassionate Access Program Office at 604.877.6000 x 6277 or [email protected] DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES Therapy for Metastatic Castration-Sensitive Prostate Cancer using abiraterone tablet Genitourinary UGUMCSPABI* R Abiraterone and Prednisone Palliative Therapy for Metastatic Castration Resistant Prostate Cancer abiraterone tablet Genitourinary UGUPABI R Using Abiraterone and prednisone acitretin capsule Lymphoma reversal of early dysplastic and neoplastic stem changes LYNOS I first-line treatment of epidermal
    [Show full text]
  • Persistent Gestational Trophoblastic Disease Is Potentially Fatal, but the Majority of Patients Are Cured with Chemotherapy
    British Journal of Cancer (2000) 82(9), 1547–1552 © 2000 Cancer Research Campaign DOI: 10.1054/ bjoc.2000.1176, available online at http://www.idealibrary.com on Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease LS Dobson, PC Lorigan, RE Coleman and BW Hancock Gestational Trophoblastic Disease Centre, Weston Park Hospital, Sheffield, UK Summary Persistent gestational trophoblastic disease is potentially fatal, but the majority of patients are cured with chemotherapy. Any developments in treatment are therefore being directed towards maintaining efficacy and reducing toxicity. We evaluated efficacy and toxicity of methotrexate, etoposide and dactinomycin (MEA) as first-line therapy for high risk disease and etoposide and dactinomycin (EA) as second-line therapy for methotrexate-refractory low risk disease in a retrospective analysis of 73 patients (38 MEA, 35 EA) treated since 1986 at a supra-regional centre. The median follow-up period was 5.5 years and the median number of cycles received was 7. The overall complete response rate was 85% (97% for EA, 75% for MEA). Of eight patients who failed to respond, four have since died and four were cured with platinum-based chemotherapy. Alopecia was universal. Grade II or worse nausea, emesis, or stomatitis was observed in 29%, 30% and 37% respectively. Fifty-one per cent experienced grade II/III anaemia, 8% grade II or higher thrombocytopenia and 64% grade III or IV neutropenia; in six cases this was complicated by sepsis.
    [Show full text]
  • Dactinomycin
    Dactinomycin DRUG NAME: Dactinomycin 1 SYNONYM(S) : actinomycin D, actinomycin C1 COMMON TRADE NAME(S): COSMEGEN® CLASSIFICATION: antitumour antibiotic Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM OF ACTION: Dactinomycin is an antineoplastic antibiotic derived from Streptomyces parvullus.2 Stable complexes are formed with DNA through intercalation and DNA-dependent RNA synthesis is selectively inhibited.1-3 Protein and DNA synthesis are inhibited to a lesser extent.3 Dactinomycin is cell cycle phase-nonspecific1. Dactinomycin is an immunosuppressive agent.3 PHARMACOKINETICS: Oral Absorption poor3 Distribution rapid; high concentrations in bone marrow and nucleated cells3; extensively bound to body tissues cross blood brain barrier? <10% volume of distribution no information found plasma protein binding not highly protein bound Metabolism minimal active metabolite(s) none inactive metabolite(s)3 small amounts of monolactones have been recovered in urine Excretion rapidly cleared from plasma (85% within 2 min) urine 12-20% of dose recovered within 24 h, 15% of dose recovered unchanged after 1 week feces 50-90% of dose excreted in bile within 24 h, 15% of dose recovered after 1 week terminal half life 36 hours, possibly prolonged with hepatic dysfunction clearance no information found Adapted from standard reference2 unless specified otherwise. USES: Primary uses: Other uses: *Gestational trophoblastic tumour *Ewing’s sarcoma *Rhabdomyosarcoma Ovarian germ cell tumour3 *Wilms’ tumour Kaposi’s sarcoma4 5 Malignant melanoma 3,6 Testicular cancer *Health Canada approved indication BC Cancer Drug Manual© All rights reserved. Page 1 of 8 Dactinomycin This document may not be reproduced in any form without the express written permission of BC Cancer Provincial Pharmacy.
    [Show full text]
  • Dactinomycin for INJECTION, USP
    Dactinomycin FOR INJECTION, USP 10 DIGIT NDC STRENGTH SIZE WHOLESALE NUMBERS WEB LISTING 39822-2100-2 ABC 10229241 500 mcg 1 Cardinal 5557707 11 DIGIT NDC (0.5 mg) per vial vial McKesson 3975687 39822-2100-02 Morris Dickson 772301 OTHER INFORMATION PRESERVATIVE FREE LATEX FREE STOPPER CONTROLLED ROOM TEMPERATURE STORAGE - - - BARCODED FOR PATIENT SAFETY Dactinomycin FOR INJECTION, USP HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use • Regional Perfusion in Locally Recurrent and Locoregional Solid Malignancies: Dactinomycin for Injection safely and effectively. See full prescribing • Lower Extremity or Pelvis: The recommend dose is 50 mcg/kg once with information for Dactinomycin for Injection. melphalan. (2.6) ◦ Upper Extremity: The recommended dose is 35 mcg/kg once with melphalan. (2.6) Dactinomycin for Injection for intravenous use Initial U.S. Approval: 1964 DOSAGE FORMS AND STRENGTHS For injection: 500 mcg as a lyophilized powder in a single-dose vial. (3) RECENT MAJOR CHANGES • Dosage and Administration, Recommended Dosage for Wilms Tumor (2.1) CONTRAINDICATIONS 8/2018 None. (4) • Dosage and Administration, Recommended Dosage for Ewing Sarcoma (2.3) 8/2018 WARNINGS AND PRECAUTIONS • Secondary Malignancy or Leukemia: Increased risk of secondary malignancies INDICATIONS AND USAGE following treatment. (5.1) Dactinomycin for injection is an actinomycin indicated for the treatment of: • Veno-occlusive Disease: Can cause severe or fatal VOD. Monitor for elevations in • adult and pediatric patients with Wilms tumor, as part of a multi-phase, AST, ALT, total bilirubin, hepatomegaly, weight gain, or ascites. Consider delaying combination chemotherapy regimen. (1.1) next dose.
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • Process for Producing Arsenic Trioxide Formulations
    (19) TZZ_964557B_T (11) EP 1 964 557 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/285 (2006.01) A61K 33/36 (2006.01) 02.01.2013 Bulletin 2013/01 A61P 35/02 (2006.01) (21) Application number: 08075200.9 (22) Date of filing: 10.11.1998 (54) Process for producing arsenic trioxide formulations Verfahren zur Herstellung von Arsentrioxidformulierungen Procédé de production de formulations à base de trioxide d’arsenic (84) Designated Contracting States: (74) Representative: Warner, James Alexander et al AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Carpmaels & Ransford MC NL PT SE One Southampton Row London (30) Priority: 10.11.1997 US 64655 P WC1B 5HA (GB) (43) Date of publication of application: (56) References cited: 03.09.2008 Bulletin 2008/36 • KWONG Y L ET AL: "Delicious poison: Arsenic trioxide for the treatment of leukemia" BLOOD, (60) Divisional application: vol. 89, no. 9, 1 May 1997 (1997-05-01), pages 10177319.0 / 2 255 800 3487-3488, XP002195910 • SHEN S-X ET AL: "USE OF ARSENIC TRIOXIDE (62) Document number(s) of the earlier application(s) in (AS2O3) IN THE TREATMENT OF ACUTE accordance with Art. 76 EPC: PROMYELOCITIC LEUKEMIA (APL): II. CLINICAL 98957803.4 / 1 037 625 EFFICACY AND PHARMACOKINETICS IN RELAPSED PATIENTS" BLOOD, W.B. (73) Proprietor: MEMORIAL SLOAN-KETTERING SAUNDERS, PHILADELPHIA, VA, US, vol. 89, no. CANCER CENTER 9, 1 May 1997 (1997-05-01), pages 3354-3360, New York, NY 10021 (US) XP000891715 ISSN: 0006-4971 • KONIG ET AL: "Comparative activity of (72) Inventors: melarsoprol and arsenic trioxide in chronic B - • Warrell, Raymond, P., Jr.
    [Show full text]
  • WILMS TUMOUR PI Wilms-1 Protocol
    WILMS TUMOUR PI Wilms-1 Protocol NCCN Pacific Island Working Group Clinical Members Scott Macfarlane Peter Bradbeer Jane Skeen Rob Corbett Siobhan Cross Radhika Sandilya PI Wilms -1 Updated 1 June 2018 1 WILMS TUMOUR PROTOCOL – PI WT #1 Source-National Wilms Tumour Study – 5 (NWTS-5) and for Fiji SIOP Umbrella Study 2016. 1.0 BACKGROUND 2.0 TREATMENT PLAN 3.0 AGENT INFORMATION Dactinomycin Doxorubicin Vincristine 4.0 PATHOLOGY 5.0 STAGING 6.0 Pre-TREATMENT EVALUATION 7.0 REGISTRATION 8.0 EVALUATION DURING THERAPY AND FOLLOWING THERAPY 9.0 TREATMENT PLAN AND MODIFICATIONS 9.1 Chemotherapy Guidelines 9.2 Surgical Guidelines 9.3 Management of Bilateral Wilms Tumour 9.4 Inoperable Tumours 9.5 Criteria for Modification of Therapy PARENT INFORMATION SHEETS APPENDICES: Appendix I – Schema for Tonga,Samoa and Vanuatu Appendix II –Schema for Fiji Appendix III- Pneumocystis prophylaxis 1.0 BACKGROUND Wilms tumour is the most frequent malignant renal tumour in children., and accounts for 6-8% of paediatric malignancies. In 1969, the paediatric divisions of two cooperative groups Acute Leukaemia Group B and the Southwest Cancer Chemotherapy Group, the Children's Cancer Study Group and several independent institutions joined together to form the National Wilms Tumour Study (NWTS) Group. Four clinical trials have been completed. As the result of these studies, the survival rate of children with Wilms tumour has risen from 20% two years after diagnosis to 90% two years after diagnosis. This success has been the result of collaborative efforts among surgeons, paediatricians, pathologists and radiation oncologists. Prompt surgical excision of the renal tumour, followed by post- operative radiation therapy, as indicated, and adjuvant chemotherapy have contributed to these good results.
    [Show full text]
  • EP/EMA Therapy (Etoposide Cisplatin/Etoposide Methotrexate Dactinomycin)
    NCCP Chemotherapy Regimen EP/EMA Therapy (Etoposide CISplatin/Etoposide Methotrexate DACTINomycin) INDICATIONS FOR USE: Regimen *Reimbursement INDICATION ICD10 Code Status Treatment of women with high-risk Gestational Trophoblastic Neoplasia D39 00264a Hospital (GTN) who have not responded or have relapsed from treatment with EMA/CO. GTN and hepatic metastases D39 00264b Hospital Women with GTN and hepatic metastases at presentation *If the reimbursement statusi is not defined, the indication has yet to be assessed through the formal HSE reimbursement process. TREATMENT: The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patients individual clinical circumstances. Treatment with etoposide and CISplatin (EP) alternates every 7 days with etoposide, methotrexate and DACTINomycin (EMA) and is administered continuously until normalization of hCG values or unacceptable toxicity develops. Patients with high-risk disease should have maintenance therapy for 3 cycles (6 weeks) after normalisation of hCG values. This may be extended to 4 cycles (8 weeks) in patients with poor prognostic features such as liver metastases with or without brain metastases. Published: 20/06/2016 NCCP Regimen: EP/EMA Therapy Version number: 2 Review: 07/02/2020 Tumour Group: Gynaecology ISMO Contributor: Prof Maccon Keane Page 1 of 5 NCCP Regimen Code: 00264 The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment.
    [Show full text]
  • Standard Oncology Criteria C16154-A
    Prior Authorization Criteria Standard Oncology Criteria Policy Number: C16154-A CRITERIA EFFECTIVE DATES: ORIGINAL EFFECTIVE DATE LAST REVIEWED DATE NEXT REVIEW DATE DUE BEFORE 03/2016 12/2/2020 1/26/2022 HCPCS CODING TYPE OF CRITERIA LAST P&T APPROVAL/VERSION N/A RxPA Q1 2021 20210127C16154-A PRODUCTS AFFECTED: See dosage forms DRUG CLASS: Antineoplastic ROUTE OF ADMINISTRATION: Variable per drug PLACE OF SERVICE: Retail Pharmacy, Specialty Pharmacy, Buy and Bill- please refer to specialty pharmacy list by drug AVAILABLE DOSAGE FORMS: Abraxane (paclitaxel protein-bound) Cabometyx (cabozantinib) Erwinaze (asparaginase) Actimmune (interferon gamma-1b) Calquence (acalbrutinib) Erwinia (chrysantemi) Adriamycin (doxorubicin) Campath (alemtuzumab) Ethyol (amifostine) Adrucil (fluorouracil) Camptosar (irinotecan) Etopophos (etoposide phosphate) Afinitor (everolimus) Caprelsa (vandetanib) Evomela (melphalan) Alecensa (alectinib) Casodex (bicalutamide) Fareston (toremifene) Alimta (pemetrexed disodium) Cerubidine (danorubicin) Farydak (panbinostat) Aliqopa (copanlisib) Clolar (clofarabine) Faslodex (fulvestrant) Alkeran (melphalan) Cometriq (cabozantinib) Femara (letrozole) Alunbrig (brigatinib) Copiktra (duvelisib) Firmagon (degarelix) Arimidex (anastrozole) Cosmegen (dactinomycin) Floxuridine Aromasin (exemestane) Cotellic (cobimetinib) Fludara (fludarbine) Arranon (nelarabine) Cyramza (ramucirumab) Folotyn (pralatrexate) Arzerra (ofatumumab) Cytosar-U (cytarabine) Fusilev (levoleucovorin) Asparlas (calaspargase pegol-mknl Cytoxan (cyclophosphamide)
    [Show full text]
  • Phase I/II Study of the Mesothelin-Targeted Immunotoxin LMB-100 with Nab-Paclitaxel For
    Author Manuscript Published OnlineFirst on December 2, 2019; DOI: 10.1158/1078-0432.CCR-19-2586 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Alewine et al., Clinical Cancer Research, Final 10/25/2019 Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with nab-paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma Running title: LMB-100 + NAB-paclitaxel in PDAC Christine Alewine1*, Mehwish I. Ahmad2, Cody J. Peer3, Zishuo Hu4, Min-Jung Lee5, Akira Yuno5, Jessica Kindrick3, Anish Thomas5, Seth M. Steinberg6, Jane B. Trepel5, William D. Figg3, Raffit Hassan7, Ira Pastan1 1Laboratory of Molecular Biology, 2Office of Research Nursing, 3Clinical Pharmacology Program, 4Medical Oncology Service, 5Developmental Therapeutics Branch, 6Biostatistics and Data Management Section, and 7Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264 Keywords: immunotoxin, mesothelin, pancreatic cancer This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research (Project No. ZIA BC 011652) *Corresponding author: Dr. Christine Alewine, Laboratory of Molecular Biology, National Cancer Institute, 37 Convent Drive, Room 5116, Bethesda, MD 20892-4264 Tel: (240) 760-6146; email: [email protected] 1 Downloaded from clincancerres.aacrjournals.org on September 26, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on December 2, 2019; DOI: 10.1158/1078-0432.CCR-19-2586 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Alewine et al., Clinical Cancer Research, Final 10/25/2019 The authors declare no potential conflicts of interest.
    [Show full text]